>   Structural Summary
100% seqID Fv Structure5tru [Fvs: HL, hl], 5xj3 [Fvs: AB, DE, GH, JK], 6jc2 [Fvs: HL], 6rp8 [Fvs: HL, hl], 7elx [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
Highest Clinical Trial (January '23)Approved
Estimated Status (January '23)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2005
INN Year Recommended2006
Companies InvolvedAduro BioTech, AIO Studien gGmbH, Australian and New Zealand Urogenital and Prostate Cancer Group, Bavarian Nordic, Big Ten Cancer Research Consortium, BioGene Pharmaceutical, Bristol-Myers Squibb, Canadian Cancer Trials Group, Dana-Farber Cancer Institute, European Thoracic Oncology Platform, Grupo Espanol Multidisciplinar de Melanoma, Icahn School of Medicine at Mount Sinai, Intergroupe Francophone de Cancerologie Thoracique, Ludwig Institute for Cancer Research, Massachusetts General Hospital, Medarex, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), National University Hospital (Singapore), Northwestern University, Olivia Newton-John Cancer Research Institute, OncoTherapy Science, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University College London, University of California at San Francisco, University of Texas M. D. Anderson Cancer Center
Conditions ApprovedMalignant melanoma, Renal cell carcinoma
Conditions ActiveColorectal cancer, Non-small cell lung cancer, Gastric cancer, Glioblastoma, Head and neck cancer, Mesothelioma, Oesophageal cancer, Prostate cancer, Small cell lung cancer, Urogenital cancer, Adrenocortical carcinoma, Breast cancer, CNS cancer, Gastrointestinal cancer, Genitourinary disorders, Gynaecological cancer, Liver metastases, Meningeal carcinomatosis, Myelodysplastic syndromes, Neuroendocrine tumours, Ovarian cancer, Pancreatic cancer, Penile cancer, Solid tumours, Thyroid cancer, Uveal melanoma, Diffuse large B cell lymphoma, Liver cancer, Lung cancer, Glioma
Conditions DiscontinuedHIV infections, Lymphoma

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy